Ibex Medical Analytics (Ibex), a leader in clinical-grade AI-powered pathology, today announced a strategic collaboration with HNL Lab Medicine, a leading multi-regional medical laboratory in the ...

Prostate cancer is the most common cancer in men and is second most common cause of cancer deaths. Importantly, the annual rates of prostate cancer incidence continue to rise. This session will delve ...

Prostate cancer stands as a prevalent threat to men's health, ranking second in cancer-related deaths in the United States. Each year, approximately 250,000 men in the U.S. receive a prostate cancer ...

Individual patient data (IPD) analysis of early PSA nadir in ARASENS, LATITUDE, and TITAN: Training and validation of a novel model. Assessing genomic instability (GI) by shallow whole-genome ...

The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...

Extended analyses: Combined androgen blockade (CAB) therapy with bicalutamide vs. luteinizing hormone-releasing hormone agonist (LHRHa) monotherapy in Japanese men with untreated advanced prostate ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug ...

Benefits include better discrimination between risk levels. (HealthDay News) — Patient-centered pathology reports (PCPR) help patients to understand prostate cancer results better than current ...

Prostate cancer has distinct genetic properties in different groups of men that could be targeted to improve patient outcomes, new research suggests. Prostate cancer has distinct genetic properties in ...